The Tokyo Olympics may not happen.
Just days ahead of the games, Japan is seeing a significant number of new cases, leading to calls to cancel the Games. Worse, hospitals in Osaka are at a breaking points, says The Sun.
“The Olympics should be stopped, because we already have failed to stop the flow of new variants from England, and next might be an inflow of Indian variants,” said Akira Takasu, the head of emergency medicine at Osaka Medical, as also quoted by The Sun. “70,000 or 80,000 athletes and the people will come to this country from around the world. This may be a trigger for another disaster in the summer.”
In addition, the Head of the Tokyo Olympics, Toshiro Muto says the games could still be canceled. According to the U.S. Sun, Muto has said, “We have agreed that based on the coronavirus situation, we will convene five-party talks again. At this point, the coronavirus cases may rise or fall, so we will think about what we should do when the situation arises.”
With the virus only getting worse – again – vaccine stocks are back in the spotlight.
Some of the top stocks to consider include:
Pfizer (PFE) and BioNTech (BTNX) recently said their vaccine is highly effective against the Delta variant, and was just granted priority review for full U.S. approval.
“Pfizer and BioNTech completed the rolling submission of the BLA in May 2021. The application includes clinical data from the pivotal Phase 3 clinical trial of the vaccine, where the vaccine’s efficacy and favorable safety profile were observed up to six months after the second dose,” according to a BioNTech press release.
Moderna (MRNA) is another top vaccine stock to consider. The company just partnered with Takeda, and the Japanese government on additional 50 million vaccine doses.
Ocugen (OCGN) could push higher with new pandemic fears. For one, the company still has a path to get its vaccine in the U.S. market. Two, the company is working on authorization to get that vaccine into Canada, as well. Just over the last few days, OCGN announced it initiated a rolling submission to Health Canada following Phase 3 clinical results, which demonstrated efficacy and safety in nearly 26,000 adults.